---
title: "Leqvio (inclisiran) in hypercholesterolemia: Clinical trials questions"
description: "Clinical trials questions on Leqvio (inclisiran) in hypercholesterolemia, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cardiovascular outcomes, Study results, Subgroup results, and Long-term results. Questions: Does Leqvio reduce heart attacks, strokes, or cardiovascular deaths? How much does Leqvio lower LDL-C vs placebo in ASCVD (ORION-10)? Does Leqvio lower ApoB and non-HDL cholesterol (ORION-10)? How many patients reached LDL-C below 70 mg/dL on Leqvio (ORION-10)? 5 further questions follow. 9 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Leqvio (inclisiran) in hypercholesterolemia: Clinical trials questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Leqvio](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf)

Clinical trials questions that apply to every indication of Leqvio are on [Leqvio (inclisiran), all indications: Clinical trials](https://www.evicenter.com/medical-information/leqvio/clinical-trials).

## Cardiovascular outcomes

<a id="leqvio-cv-outcomes"></a>

### Does Leqvio reduce heart attacks, strokes, or cardiovascular deaths?

> “The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.”

Source: [LEQVIO: 2026 Guidelines Information | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/guidelines#:~:text=The%20effect%20of%20LEQVIO%20on,mortality%20has%20not%20been%20determined.)

Note: This sentence appears on the guidelines and unmet-need pages of the Leqvio HCP site, as captured on November 14, 2026. The Prescribing Information (revised 08/2026) does not include it.

## Study results

<a id="leqvio-orion-10-ldl"></a>

### How much does Leqvio lower LDL-C vs placebo in ASCVD (ORION-10)?

> “Trial 1 (ORION-10, NCT03399370) was a multicenter, double-blind, randomized, placebo-controlled 18-month 
> trial in which 1,561 adults with ASCVD were randomized 1:1 to receive subcutaneous injections of either 
> LEQVIO 284 mg (n = 781) or placebo (n = 780) on Day 1, Day 90, Day 270, and at Day 450. Patients were 
> taking a maximally tolerated dose of statin with or without other lipid modifying therapy and required 
> additional LDL-C reduction.”

Source: [LEQVIO: Prescribing information, page 9, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=9)

> “The primary efficacy outcome measure in Trial 1 was the percent change from baseline to Day 510 in LDL-C. 
> The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to 
> Day 510 was -52% (95% CI: -56%, -49%; p < 0.0001).”

Source: [LEQVIO: Prescribing information, page 10, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=10)

<a id="leqvio-orion-10-lipids"></a>

### Does Leqvio lower ApoB and non-HDL cholesterol (ORION-10)?

> “Table 2: Changes in Lipid Parameters in Adults with Hypercholesterolemia and ASCVD on Maximally 
> Tolerated Statin Therapy (Mean % Change from Baseline to Day 510 in Trial 1)  
> Treatment Group 
> LDL-C 
> Total 
> Cholesterol 
> Non-HDL-C 
> ApoB 
> Day 510 (mean percentage change from baseline)<sup>a</sup> 
> Placebo (n = 780) 
> 1 
> 0 
> 0 
> -2 
> LEQVIO 
> (n = 781) 
> -51 
> -34 
> -47 
> -45 
> Difference from placebo (LS Mean) 
> (95% CI) 
> -52 
> (-56, -49) 
> -33 
> (-35, -31) 
> -47 
> (-50, -44) 
> -43 
> (-46, -41)”

Source: [LEQVIO: Prescribing information, page 10, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=10)

Note: Table 2 gives the placebo row, the LEQVIO row, and the difference from placebo (LS mean, 95% CI), each in the column order LDL-C, total cholesterol, non-HDL-C, and ApoB; values are mean percentage change from baseline to Day 510.

<a id="leqvio-orion-10-ldl-targets"></a>

### How many patients reached LDL-C below 70 mg/dL on Leqvio (ORION-10)?

> “In ORION-10 (N=1561), on top of a maximally tolerated statin, LEQVIO<sup>®</sup> demonstrated:”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=In%20ORION%2D10%20%28N%3D1561%29%2C%20on%20top,demonstrated%3A)

> “84% of patients receiving LEQVIO achieved LDL-C target* <70 mg/dL vs 18% with placebo at Month 17.<sup>2</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=84%25%20of%20patients%20receiving%20LEQVIO,18%25%20with%20placebo%20at%20Month)

> “75% of patients receiving LEQVIO achieved an LDL-C <55 mg/dL vs 4% of patients on placebo at Month 17.<sup>3,4</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=75%25%20of%20patients%20receiving%20LEQVIO,patients%20on%20placebo%20at%20Month)

> “*LDL-C target was <70 mg/dL for patients with ASCVD.<sup>1</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=%2ALDL%2DC%20target%20was%20%3C70%20mg%2FdL%20for%20patients%20with)

Note: The trial targets are those defined in the footnote; the Leqvio HCP site states that they align with the 2018 AHA/ACC cholesterol guideline. The site gives the 2026 guideline targets separately (see the question on the 2026 guideline LDL-C targets).

<a id="leqvio-orion-11-ldl"></a>

### How much did Leqvio lower LDL-C vs placebo in ORION-11?

> “Trial 2 (ORION-11, NCT03400800) was a multicenter, double-blind, randomized, placebo-controlled 18-month 
> trial in which 1,617 adults with ASCVD or increased risk for ASCVD were randomized 1:1 to receive 
> subcutaneous injections of either LEQVIO 284 mg (n = 810) or placebo (n = 807) on Day 1, Day 90, Day 270, 
> and at Day 450. Patients were taking a maximally tolerated dose of statin with or without other lipid modifying 
> therapy and required additional LDL-C reduction.”

Source: [LEQVIO: Prescribing information, page 11, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=11)

> “The primary efficacy outcome measure in Trial 2 was the percent change from baseline to Day 510 in LDL-C. 
> The difference between the LEQVIO and placebo groups in mean percentage change in LDL-C from baseline to 
> Day 510 was -50% (95% CI: -53%, -47%; p < 0.0001).”

Source: [LEQVIO: Prescribing information, page 11, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=11)

> “Adults with hypercholesterolemia and ASCVD or at increased risk of CVD<sup>‡</sup> in ORION-11<sup>1</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=Adults%20with%20hypercholesterolemia%20and%20ASCVD%20or,in)

> “<sup>‡</sup>Factors that increase risk of CVD include HeFH, T2DM, or 10-year risk of ≥20%.<sup>7</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=that%20increase%20risk%20of%20CVD%20include%20HeFH%2C%20T2DM%2C%20or%2010%2Dyear%20risk%20of)

This passage is in a collapsed section of the page; select: Adults with hypercholesterolemia and ASCVD or at increased risk of CVD in ORION-11

> “81% of patients
> treated with LEQVIO achieved guideline-recommended target<sup>§</sup> compared to 18% of patients with placebo at Month 17<sup>5,6</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=81%25%20of%20patients,patients%20with%20placebo%20at%20Month)

This passage is in a collapsed section of the page; select: Adults with hypercholesterolemia and ASCVD or at increased risk of CVD in ORION-11

> “<sup>§</sup>LDL-C <70 mg/dL for ASCVD and LDL-C <100 mg/dL for patients at increased risk of CVD.<sup>6‡</sup>”

Source: [LEQVIO: Clinical Trial Data | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/pivotal-trials#:~:text=%3C70%20mg%2FdL%20for%20ASCVD%20and,patients%20at%20increased%20risk%20of)

This passage is in a collapsed section of the page; select: Adults with hypercholesterolemia and ASCVD or at increased risk of CVD in ORION-11

Note: The trial targets are those defined in the footnote; the Leqvio HCP site states that they align with the 2018 AHA/ACC cholesterol guideline. The site gives the 2026 guideline targets separately (see the question on the 2026 guideline LDL-C targets).

<a id="leqvio-v-inception"></a>

### Does Leqvio lower LDL-C after acute coronary syndrome vs usual care (V-INCEPTION)?

> “V-INCEPTION evaluated the efficacy and safety of LEQVIO plus usual care vs usual care alone in adults (N=400) who needed additional LDL-C lowering after a coronary event. Adults were screened within 5 weeks from their coronary event and the median time from discharge to treatment was 34 days.<sup>7</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=V%2DINCEPTION%20evaluated%20the%20efficacy%20and,discharge%20to%20treatment%20was%2034)

> “<sup>‡</sup>An event is defined as acute coronary syndrome (unstable angina, STEMl, or NSTEMI).<sup>7</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=event%20is%20defined%20as%20acute%20coronary%20syndrome%20%28unstable%20angina%2C%20STEMl%2C%20or)

> “Usual care included statin and nonstatin, LDL-C–lowering treatment as considered appropriate by treating clinicians. At Day 330 (n=171), most patients in the usual care arm remained on statins only (67.8%, n=116), with a minority of patients receiving any additional nonstatin LDL-C–lowering therapy.<sup>8</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=Usual%20care%20included%20statin%20and,receiving%20any%20additional%20nonstatin%20LDL%2DC%E2%80%93lowering)

> “LEQVIO demonstrated a 47% LDL-C reduction difference from usual care alone at Day 330.”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=LEQVIO%20demonstrated%20a%2047%25%20LDL%2DC,care%20alone%20at%20Day%20330.)

> “67% of patients achieved LDL-C target <70 mg/dL (co-primary endpoint) in the LEQVIO arm compared with 28% of patients receiving usual care alone.<sup>7</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=67%25%20of%20patients%20achieved%20LDL%2DC,of%20patients%20receiving%20usual%20care)

> “54% of patients achieved LDL-C target of <55 mg/dL (secondary endpoint) in the LEQVIO arm compared with 14% of patients receiving usual care alone.<sup>7</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=54%25%20of%20patients%20achieved%20LDL%2DC,of%20patients%20receiving%20usual%20care)

> “Limitations: Usual care did not reflect “best practice” with little use of guideline-recommended, nonstatin therapy; therefore, a comparison of efficacy or safety of LEQVIO vs other nonstatin therapies cannot be made. Not all participants in the LEQVIO arm received 3 doses of LEQVIO. LEQVIO use (1.5%; n=3) was not restricted in the usual care arm. The open-label design presented inherent limitations, including higher dropout rates.<sup>7,8</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=Limitations%3A%20Usual%20care%20did%20not,inherent%20limitations%2C%20including%20higher%20dropout)

Note: The page cites a presentation at the National Lipid Association 2025 Scientific Sessions for V-INCEPTION.

<a id="leqvio-v-initiate"></a>

### Did early Leqvio reduce statin discontinuation vs usual care (V-INITIATE)?

> “Study design for V-INITIATE: A 12-month, randomized, open-label, phase 3b study in adults with ASCVD (N=450) evaluated the efficacy and safety of early initiation with LEQVIO immediately upon failure to reach LDL-C <70 mg/dL on maximally tolerated statin vs usual care in a real-world setting.<sup>9</sup>
>
> The co-primary end points were percentage change in LDL-C from baseline and statin discontinuation rate.<sup>9</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=Study%20design%20for%20V%2DINITIATE%3A%20A,from%20baseline%20and%20statin%20discontinuation)

> “In the usual care arm, most patients (73%) remained on statins only, with a minority of patients receiving any additional nonstatin LDL-C–lowering therapy, including 10 patients who received at least 1 dose of LEQVIO.<sup>9</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=In%20the%20usual%20care%20arm%2C,at%20least%201%20dose%20of)

> “6% of patients in the LEQVIO arm vs 17% of patients in the usual care arm discontinued statins<sup>††</sup>
> [-11% (97.5% CI: -18, -3)]<sup>9</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=6%25%20of%20patients%20in%20the,%5B%2D11%25%20%2897.5%25%20CI%3A%20%2D18%2C)

> “<sup>††</sup>Statin discontinuation defined as no statin use for ≥30 days in patients without a history of statin intolerance.<sup>9</sup>”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=discontinuation%20defined%20as%20no%20statin,without%20a%20history%20of%20statin)

> “Limitations: Usual care did not reflect “best practice” with little use of guideline-recommended nonstatin therapy; therefore, a comparison of efficacy or safety of LEQVIO vs other nonstatin therapies cannot be made. LEQVIO use (n=10) was permitted in the usual care arm which may impact the effectiveness of comparisons. Although the study was designed to mimic clinical practice, statin discontinuation rates may not reflect the real world due to participants’ potential behavior change as a result of being part of a study. The open-label design has the potential for bias and may present difficulties in the interpretation of results.”

Source: [LEQVIO: Real-World Setting | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/real-world-setting#:~:text=Limitations%3A%20Usual%20care%20did%20not%20reflect%20%E2%80%9Cbest%20practice%E2%80%9D%20with%20little%20use%20of,-guideline%2Drecommended%20nonstatin%20therapy%3B)

Note: The page presents the V-INITIATE LDL-C results as graphics, so they are not quoted.

## Subgroup results

<a id="leqvio-subgroups"></a>

### Does Leqvio lower LDL-C similarly across age, sex, and diabetes subgroups?

> “In a pooled analysis of Trial 1 and Trial 2, the observed treatment effect was similar across predefined 
> subgroups, such as sex, age, race, disease characteristics, geographic regions, presence of diabetes, body mass 
> index, baseline LDL-C levels, and intensity of statin treatment.”

Source: [LEQVIO: Prescribing information, page 12, captured 2026-11-14](https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf#page=12)

Note: Trial 1 is ORION-10 and Trial 2 is ORION-11 in the Prescribing Information.

## Long-term results

<a id="leqvio-long-term-efficacy"></a>

### How well does Leqvio lower LDL-C long term (ORION-8 extension)?

> “In ORION-8 (N=3274), an open-label extension study
>
> ~80% of patients achieved guideline-recommended LDL-C target<sup>§</sup> EOS<sup>‖</sup>
>
> (78%; 95% CI: 77%, 80%)<sup>7</sup>
>
> Patients achieved ~50% LDL-C reduction at EOS
>
> n=2731 (mean percentage change in LDL-C was -49% at EOS<sup>‖</sup>; 95% CI: -50%, -48%)<sup>7</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=In%20ORION%2D8%20%28N%3D3274%29%2C%20an%20open%2Dlabel,95%25%20CI%3A%20%2D50%25%2C)

> “Study Design: ORION-8, an open-label extension trial that included 3274 adults from ORION-9, ORION-10, ORION-11, and ORION-3, was designed to assess the long-term safety, efficacy, and tolerability of LEQVIO in patients with ASCVD or at increased risk for CVD<sup>†</sup> and elevated LDL-C, despite ongoing treatment with lipid-lowering therapy.<sup>5,7</sup>
>
> Limitations: Study was not blinded nor controlled and includes inherent self-selection bias for continuing onto the extension trial. The open-label design and absence of a control group may present difficulties in the interpretation of results, allowing comparisons only to baseline values.<sup>7§</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=Study%20Design%3A%20ORION%2D8%2C%20an%20open%2Dlabel,allowing%20comparisons%20only%20to%20baseline)

> “<sup>‡</sup>209 (6.4%) patients had exposure to LEQVIO for 6+ years, 213 (6.5%) patients had exposure to LEQVIO for 5+ years, 1553 (47.4%) patients had exposure for 4+ years, and 2095 (64%) patients had exposure for 3+ years.<sup>8</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=%286.4%25%29%20patients%20had%20exposure%20to,patients%20had%20exposure%20for%203%2B)

> “<sup>§</sup>LDL-C target was <70 mg/dL for patients with ASCVD and <100 mg/dL for patients at increased risk for CVD<sup>†</sup> and aligns with the 2018 AHA/ACC Guideline.<sup>5,9</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=target%20was%20%3C70%20mg%2FdL%20for%20patients%20with%20ASCVD%20and,aligns%20with%20the%202018%20AHA%2FACC)

> “<sup>‖</sup>End of study was defined as day 1080 or ≥90 days after the last LEQVIO dose.<sup>7</sup>”

Source: [LEQVIO: Long-Term Efficacy | LEQVIO® (inclisiran) | HCP, captured 2026-11-14](https://www.leqviohcp.com/efficacy/long-term-efficacy#:~:text=of%20study%20was%20defined%20as,days%20after%20the%20last%20LEQVIO)

Note: ORION-8 included patients from ORION-9, which the Prescribing Information describes as a trial in adults with HeFH.

## Related pages
- [Medical information: Leqvio (inclisiran): Hypercholesterolemia](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia)
- [Indication](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/indication)
- [Safety](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/safety)
- [Specific populations](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/leqvio--hypercholesterolemia/guidelines)
